| Myelodysplastic Syndromes: A Review of Therapeutic Progress Over the Past 10 Years |
|
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
| Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
|
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
| Getting personal with myelodysplastic syndromes: is now the right time? |
|
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
| Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter? |
|
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
| Management of aplastic anemia after failure of frontline immunosuppression |
|
Expert Review of Hematology |
Aplastic Anemia |
| Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? |
|
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
| Novel therapeutic choices in immune aplastic anemia |
|
F1000Research |
Aplastic Anemia |
| How we diagnose Myelodysplastic syndromes |
|
Frontiers in Oncology |
Myelodysplastic Syndromes (MDS) |
| The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes |
|
Frontiers in Oncology |
Aplastic Anemia |
| Targeting the Microenvironment in MDS: The Final Frontier |
|
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
